Flare Therapeutics

aid: flare-therapeutics
name: Flare Therapeutics
description: Flare Therapeutics is a clinical-stage biotechnology company headquartered at 400 Technology Square, Cambridge,
  Massachusetts, developing small-molecule precision medicines against transcription factors — a target class long considered
  undruggable. Its platform combines a "switch site" hypothesis with cell-based ligand discovery and chemoproteomics to find
  binding pockets on transcription factors that control cancer cell states. The company launched publicly in May 2021 with
  an $82 million Series A led by Third Rock Ventures, and closed an $85 million insider-led Series C on 30 June 2026 led by
  Third Rock Ventures and Nextech Invest with Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital,
  Eli Lilly, Novartis, Agent Capital and Eventide Asset Management participating, appointing Anna Protopapas as Chief Executive
  Officer at the same time. Its clinical-stage lead FX-909 is a PPARG inverse agonist in advanced urothelial cancer; FX-111
  is an androgen-receptor-directed program in prostate cancer that received FDA IND clearance ahead of a clinical start in
  the third quarter of 2026. Flare also runs a discovery collaboration with Roche on undrugged transcription factor targets
  in oncology. Flare Therapeutics operates no developer program and publishes no product API, developer portal or API documentation.
  The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.flaretx.com,
  catalogued here.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: open
  trial: false
  try_now: false
  public: true
  gated: none
  gated_source:
  - onboarding
  label: Open access
  confidence: medium
  source:
  - authentication
  - rate-limits
  - security
  generated: '2026-11-06'
  method: derived
image: https://www.flaretx.com/wp-content/uploads/2021/05/Flare-website-social-card-051221.jpg
url: https://raw.githubusercontent.com/api-evangelist/flare-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Precision Medicine
- transcription-factors
- Drug Discovery
- Clinical Trials
- Life Sciences
- content-api
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- oncology
- precision-medicine
- transcription-factors
- drug-discovery
- clinical-trials
- life-sciences
- content-api
apis:
- aid: flare-therapeutics:flaretx-com-website-wordpress-rest
  name: Flare Therapeutics Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Flare Therapeutics website at www.flaretx.com: the route index
    of the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://www.flaretx.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://www.flaretx.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Plans
  url: plans/flare-therapeutics-plans-pricing.yml
- type: RateLimits
  url: rate-limits/flare-therapeutics-rate-limits.yml
- type: DomainSecurity
  url: security/flare-therapeutics-domain-security.yml
- type: Website
  url: https://www.flaretx.com/
- type: About
  url: https://www.flaretx.com/about/
- type: Science
  url: https://www.flaretx.com/science/
- type: Pipeline
  url: https://www.flaretx.com/pipeline/
- type: Publications
  url: https://www.flaretx.com/publications/
- type: News
  url: https://www.flaretx.com/news/
- type: BlogRSS
  url: https://www.flaretx.com/feed/
- type: Careers
  url: https://www.flaretx.com/join-us/
- type: Contact
  url: https://www.flaretx.com/contact/
- type: PrivacyPolicy
  url: https://www.flaretx.com/privacy-policy/
- type: TermsOfService
  url: https://www.flaretx.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/flare-therapeutics
- type: GitHubOrganization
  url: https://github.com/FlareTx
- type: SecondaryMarket
  url: https://forgeglobal.com/flare-therapeutics_stock/
- type: Authentication
  url: authentication/flare-therapeutics-authentication.yml
- type: Conventions
  url: conventions/flare-therapeutics-conventions.yml
- type: Conformance
  url: conformance/flare-therapeutics-conformance.yml
- type: ErrorCatalog
  url: errors/flare-therapeutics-problem-types.yml
- type: Lifecycle
  url: lifecycle/flare-therapeutics-lifecycle.yml
- type: DataModel
  url: data-model/flare-therapeutics-data-model.yml
- type: LLMsTxt
  url: llms/flare-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-12'
  status: enriched
  artifacts_added: 17
  pass: local-v1